XVII International Symposium on Respiratory Viral Infections
March 2015
Vancouver, Canada

Preliminary Program
As of January 3, 2015

Chairs:
W. Abdullah Brooks Centre for Vaccine Sciences (ICDDR, B), Johns Hopkins Bloomberg School of Public Health, Dhaka, Bangladesh and Baltimore, Maryland, United States
Arnold Monto Thomas Francis Jr Professor of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States

Scientific Advisory Board:
Rick Bright Biomedical Advanced Research and Development Authority (BARDA), Washington, District of Columbia United States
Nancy Cox Retired, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
Menno de Jong Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Janet Englund University of Washington, Seattle, Washington, United States
Sebastian Johnston National Heart & Lung Institute, Imperial College, London, United Kingdom
Yoshihiro Kawaoka University of Tokyo, Tokyo, Japan; University of Wisconsin, Madison Wisconsin, United States
Paul Kellam Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom
Kathy Neuzil Program for Appropriate Technology in Health (PATH], Seattle, Washington United States
Albert Osterhaus Erasmus MC, Rotterdam, The Netherlands
Malik Peiris University of Hong Kong, Hong Kong SAR, People’s Republic of China
Vadim Tsvetnitsky International AIDS Vaccine Initiative (IAVI), New York, New York United States
Thursday, March 5, 2015

15.00 – 18.00  Symposium Registration Desk Open

Friday, March 6, 2015 - Day One

07.30  Registration Desk Opens

08.30  Welcome and Introduction to Keynote

08.35 – 09.05  Keynote Address
Intervention Strategies for Respiratory Viral Disease: Past, Present and Future - Albert D.M.E. Osterhaus, Erasmus MC, Rotterdam, The Netherlands (accepted)

Session I  Influenza – Albert D.M.E. Osterhaus, Erasmus MC, Rotterdam, The Netherlands (accepted)

09.05 – 10.20  Burden of Disease in the Developing World
09.05 Prospects for Disease Control – Kathy Neuzil, Program for Appropriate Technology in Health (PATH), Seattle, Washington, United States (accepted)
09.20 South Africa – Shabir Madhi, NICD, South Africa (accepted)
09.35 Senegal – John C. Victor, Program for Appropriate Technology in Health (PATH), Seattle, Washington, United States (accepted)
09.50 Bangladesh – Kathy Sturm-Ramirez, CDC Senior Technical Lead for Influenza and Respiratory Diseases Center for Communicable Diseases ICDDR,B International Centre for Diarrhoeal Disease Research, Bangladesh (accepted)

10.05 Questions and Discussion

10.20 – 10.50 Coffee Break

10.50 – 11.15 Influenza – Where are we Now? – Albert D.M.E. Osterhaus, Erasmus MC, Rotterdam, The Netherlands (accepted)

11.15 – 11.40 Basic Research Towards Better Prevention and Treatment of Influenza – Yoshihiro Kawaoka, University of Tokyo, Tokyo, Japan; University of Wisconsin, Madison Wisconsin, United States (accepted)

11.40 – 12.05 Update on H7N9 – Malik Peiris, University of Hong Kong, Hong Kong SAR, Republic of China (accepted)

12.05 – 13.30 Lunch Break

13.30 – 13.55 Does Oseltamivir Really Work – The Report from the MUGAS Study – Arnold Monto, Thomas Francis Jr Professor of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:55 – 14:15</td>
<td><strong>Oral Presentation</strong>&lt;br&gt;Recovery of Influenza Virus and Rhinovirus RNA from Air Emitted by Patients with Laboratory-confirmed Infection – Samira Mubareka, University of Toronto, Toronto, Ontario, Canada</td>
</tr>
<tr>
<td>14:15 - 14:35</td>
<td>Oral Presentation&lt;br&gt;<strong>Session II</strong> <strong>Clinical Intervention</strong> – Menno de Jong, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands <em>(accepted)</em></td>
</tr>
<tr>
<td>14:35– 15:00</td>
<td>Overview of Needs and Targets for Treatment - Menno de Jong, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands <em>(accepted)</em></td>
</tr>
<tr>
<td>15.00 – 15.25</td>
<td>Observational Data on Hospitalized Flu – Jonathan Van Tam, Health Protection Agency, London, United Kingdom <em>(accepted)</em></td>
</tr>
<tr>
<td>15.25 - 15.55</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>15.55 – 16.25</td>
<td>Situation Update of MERS-Coronavirus – Chantal B.E.M. Reusken, Erasmus MC, Rotterdam, The Netherlands <em>(accepted)</em></td>
</tr>
<tr>
<td>16.25 – 16.50</td>
<td>Clinical Update on Monoclonals for Influenza – Jaap Goudsmit, Crucell, Leiden, The Netherlands <em>(accepted)</em></td>
</tr>
<tr>
<td>16.50 – 17.10</td>
<td>Favipiravir (T705) Development – Carol Epstein – Medivector Inc., Boston, Massachusetts, United States <em>(accepted)</em></td>
</tr>
<tr>
<td>17.10 – 17.35</td>
<td>Antivirals/Antibodies Management of Acutely Ill Patients – Thomas Luke, Naval Medical Research Center, Henry Jackson Foundation, Silver Spring, Maryland, United States <em>(accepted)</em></td>
</tr>
<tr>
<td>17.35 – 17.55</td>
<td><strong>Oral Presentation</strong>&lt;br&gt;Effect of Oseltamivir Treatment on the Severity of Symptoms in Children with Influenza – Terho Heikkinen, University of Turku, Turku, Finland</td>
</tr>
<tr>
<td>17.55 – 18.15</td>
<td><strong>Oral Presentation</strong>&lt;br&gt;Respiratory Failure and Virus Burden in Adults Hospitalized for Respiratory Syncytial Virus (RSV) Infections – Nelson Lee, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, People’s Republic of China</td>
</tr>
<tr>
<td>18.15 – 18.35</td>
<td>Oral Presentation</td>
</tr>
<tr>
<td>18.35 – 20.35</td>
<td>Welcome Reception</td>
</tr>
</tbody>
</table>
Saturday March 7, 2015 – Day 2

09.00 – 09.05 Introduction of Keynote Address – Arnold Monto, Thomas Francis Jr Professor of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States

09.05 – 09.30 Keynote Address: Ebola – Overview of Vaccines and Therapeutics and Update on Response Efforts
Gary L. Disbrow, Ph.D., Director, Biomedical Advanced Research and Development Authority (BARDA)/CBRN Division, Washington, D.C, USA (invited)

Session III

Respiratory Viral Exacerbation of Airway Disease – Sebastian Johnston, National Heart & Lung Institute, Imperial College, London, United Kingdom (accepted) and Ross P. Walton, National Heart & Lung Institute, Imperial College, London, United Kingdom (accepted)

09.30 – 09.55 Characterisation of Cellular Responses in the Airways During Rhinovirus Induced Asthma Exacerbations – Ross P. Walton, National Heart & Lung Institute, Imperial College, London, United Kingdom (accepted)

09.55 – 10.25 Coffee Break

10.25 – 10.50 Wheezing Related Interventions – James Gern, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States (accepted)

10.50 – 11.10 Oral Presentation – Young Investigator Award Recipient Sponsored by The Macrae Foundation
RSV Infection in Pregnancy and Postpartum – Helen Y. Chu, University of Washington, Seattle, Washington, United States

11.10 – 11.30 Oral Presentation
Preclinical Characterization of AL-036, a Potent Nucleoside Analog Polymerase Inhibitor for the Treatment of Rhinovirus-Triggered Exacerbations of Airway Disease – Andreas Jekle, Alios Biopharma, Inc., South San Francisco, California, United States

11.30 – 12.10 Oral Presentation X2

12.10 – 14.15 Satellite Symposium: Sponsored by GlaxoSmithKline
Boxed Lunch
XVII International Symposium on Respiratory Viral Infections  
March 6 – 8, 2015  
Vancouver, Canada  

Preliminary Program

<table>
<thead>
<tr>
<th>Session IV</th>
<th>Pathogens – Malik Peiris, University of Hong Kong, Hong Kong SAR, People’s Republic of China</th>
<th>(accepted)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30 – 14.50</td>
<td>Oral Presentation – Young Investigator Award Recipient Sponsored by The Macrae Foundation</td>
<td>Human Bocavirus-1 Primary Infection and Shedding in Infants – Emily T. Martin, University of Michigan School of Public Health, Ann Arbor, Michigan, United States</td>
</tr>
<tr>
<td>14.50 – 15.10</td>
<td>Oral Presentation – Young Investigator Award Recipient Sponsored by The Macrae Foundation</td>
<td>Viral Load as a Correlate for Symptom Severity in Hematopoietic Cell Transplant Recipients Infected with Human Rhinovirus – Alpana Waghmare, University of Washington/Seattle Children’s Hospital, Seattle, Washington, United States</td>
</tr>
<tr>
<td>14.10 – 15.10</td>
<td>Oral Presentations X3</td>
<td></td>
</tr>
<tr>
<td>15.10 – 15.40</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>16.15 – 18.00</td>
<td>Poster Session Reception</td>
<td></td>
</tr>
</tbody>
</table>
Sunday, March 8, 2015 – Day Three

Session V  Vaccination – Arnold Monto, Thomas Francis Jr Professor of Epidemiology, University of Michigan, and Ann Arbor, Michigan, United States (accepted)

09.00 – 10.05 Maternal Vaccination – chair: Janet Englund, University of Washington, Seattle, Washington, United States (accepted)

09.00 – 09.25 Progress of Maternal Vaccination – Janet Englund, University of Washington, Seattle, Washington, United States (accepted)

09.25 – 10.05 – Oral Presentation X 2

10.05 – 11.10 Toward Universal Vaccines - chair: Rick Bright, Biomedical Advanced Research and Development Authority (BARDA), Washington, D.C., United States (invited)

10.05 – 10.30 Universal Vaccines – Rick Bright, Biomedical Advanced Research and Development Authority (BARDA), Washington, D.C., United States (invited)

10.30 – 11.10 – Oral Presentation X 2

11.10 – 11.40 Coffee Break

11.40 – 13.10 Priorities for Developing and Developed Countries – chair: Abdullah Brooks, Centre for Vaccine Sciences (ICDDR, B), Johns Hopkins Bloomberg School of Public Health, Dhaka, Bangladesh and Baltimore, Maryland, United States (accepted)

11.40 – 12.05 Priorities for Developing and Developed Countries – Abdullah Brooks, Centre for Vaccine Sciences (ICDDR, B), Johns Hopkins Bloomberg School of Public Health, Dhaka, Bangladesh and Baltimore, Maryland, United States (accepted)

12.05 – 12.30 Role of RSV in Disease in Young Infants – James Nokes, KEMRI/Wellcome Trust, Kilifi, Kenya (accepted)

12.30 – 12.50 Oral Presentation
Immunogenicity and Viral Shedding of a Seasonal Trivalent Live Attenuated Influenza Virus Vaccine among Children in Bangladesh – Kristen Lewis, Program for Appropriate Technology in Health (PATH), Seattle, Washington, United States

12.50- 13.10 – Oral Presentation
Efficacy of a Single Dose of Trivalent LAIV in Prevention of Laboratory-confirmed Influenza Illness in Bangladeshi Children – Abdullah Brooks, Centre for Vaccine Sciences (ICDDR, B), Johns Hopkins Bloomberg School of Public Health, Dhaka, Bangladesh and Baltimore, Maryland, United States

13.10 - 14.45 Lunch Break
Vaccination Continued – Chair: Janet Englund, University of Washington, Seattle, Washington, United States

14.45 – 15.10  Disease Burden in Neonates and Interventions – Allison August, Novavax, Inc., Gaithersburg, Maryland, United States (accepted)

15.10 – 15.20  Oral Presentations x2

15.50 – 16.15  Respiratory Vaccines of Tomorrow – TBD

16.15 – 16.35  Oral Presentation
A Phase I Study of MED17510, an Adjuvanted RSV Vaccine, in Subjects 60 Years of Age and Older – Judith Falloon, MedImmune Inc., Gaithersburg, Maryland, United States

16.35 - 16.55  Oral Presentation
One or Two Doses of a Live Attenuated H7N9 Vaccine Followed by a Dose of an Inactivated H7N9 Vaccine are well Tolerated by Healthy Adults Aged 18-49 Years – Kawsar R. Talaat, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States

16.55 – 17.10  Meeting Conclusion